Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2014

Open Access 01-12-2014 | Case report

An Egyptian child with erythromelalgia responding to a new line of treatment: a case report and review of the literature

Authors: Samir M Al-Minshawy, Abdel-Azeem M El-Mazary

Published in: Journal of Medical Case Reports | Issue 1/2014

Login to get access

Abstract

Introduction

Erythromelalgia is a rare clinical syndrome characterized by episodic erythema, warmth and intense burning pain, which commonly involves the extremities. For those affected, this disorder may lead to significant long-term morbidity. Unfortunately, to date, no definitive therapy is available. This case report describes an Egyptian child with primary erythromelalgia that manifested at an early age and showed partial response to therapy with cetirizine hydrochloride. This anecdotal case report may have a diagnostic value for clinicians who have not seen this disorder.

Case presentation

A 34-month-old previously healthy right-handed Hamitic boy without any significant past medical history presented at the age of 2 years with episodic bilateral pain in his feet. His mother reported associated warmth and erythema localized to his feet that never extended beyond his ankle joints. This pain is triggered by exertion and/or warm temperature exposure and is relieved by cooling measures. The diagnosis of erythromelalgia was made based on the patient’s medical history and a thorough physical examination during the episodes. No evidence of local or systemic infection was present. Other causes for the symptoms were excluded by a negative extensive diagnostic work-up. Our patient did not respond to ibuprofen (15mg/kg/dose) three times a day but partial improvement with the oral non-sedating antihistaminic cetirizine hydrochloride (2.5mg/kg/once daily) was observed. When the child stopped cetirizine hydrochloride for 1 month as a test, the symptoms became aggravated and were relieved when cetirizine therapy was restarted. Cetirizine hydrochloride had not previously been reported to have this effect in children with erythromelalgia.

Conclusions

Erythromelalgia is a clinical syndrome of which the etiology, diagnosis and management are controversial. We describe a case of a 34-month-old Egyptian child with primary erythromelalgia that manifested at an early age. We believe that this is the first Egyptian case report of this kind in the literature. Partial response of this patient to cetirizine hydrochloride may grant us a new clue to understanding this mysterious condition.
Appendix
Available only for authorised users
Literature
1.
go back to reference Michiels JJ, Drenth JP, Van Genderen PJ: Classification and diagnosis of erythromelalgia and erythermalgia. Int J Dermatol. 1995, 34: 97-100. 10.1111/j.1365-4362.1995.tb03587.x.CrossRefPubMed Michiels JJ, Drenth JP, Van Genderen PJ: Classification and diagnosis of erythromelalgia and erythermalgia. Int J Dermatol. 1995, 34: 97-100. 10.1111/j.1365-4362.1995.tb03587.x.CrossRefPubMed
2.
go back to reference Buttaci CJ: Erythromelalgia: a case report and literature review. Pain Medicine. 2006, 7: 534-538. 10.1111/j.1526-4637.2006.00240.x.CrossRefPubMed Buttaci CJ: Erythromelalgia: a case report and literature review. Pain Medicine. 2006, 7: 534-538. 10.1111/j.1526-4637.2006.00240.x.CrossRefPubMed
3.
go back to reference Bouyahyaoui Y, Meziane M, Hanaae Z, Mikou O, Mernissi FZ, Baba Khouya A, Otmani S, Hida M: Primary familial erythromelalgia. A case report. Arch Pediatr. 2013, 20: 369-371. 10.1016/j.arcped.2013.01.014.CrossRefPubMed Bouyahyaoui Y, Meziane M, Hanaae Z, Mikou O, Mernissi FZ, Baba Khouya A, Otmani S, Hida M: Primary familial erythromelalgia. A case report. Arch Pediatr. 2013, 20: 369-371. 10.1016/j.arcped.2013.01.014.CrossRefPubMed
4.
go back to reference Mitchell SW: On a rare vasomotor neurosis of the extremities and on the maladies with which it may be confounded. Am J Med Sci. 1878, 76: 17-36.CrossRef Mitchell SW: On a rare vasomotor neurosis of the extremities and on the maladies with which it may be confounded. Am J Med Sci. 1878, 76: 17-36.CrossRef
5.
go back to reference Davis MD, O’Fallon WM, Rogers RS, Rooke TW: Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol. 2000, 136: 330-336.CrossRefPubMed Davis MD, O’Fallon WM, Rogers RS, Rooke TW: Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol. 2000, 136: 330-336.CrossRefPubMed
6.
go back to reference Kalgaard OM, Seem E, Kvernebo K: Erythromelalgia: a clinical study of 87 cases. J Intern Med. 1997, 242: 191-197. 10.1046/j.1365-2796.1997.00185.x.CrossRefPubMed Kalgaard OM, Seem E, Kvernebo K: Erythromelalgia: a clinical study of 87 cases. J Intern Med. 1997, 242: 191-197. 10.1046/j.1365-2796.1997.00185.x.CrossRefPubMed
7.
go back to reference Alhadad A, Wollmer P, Svensson A, Eriksson KF: Erythromelalgia: incidence and clinical experience in a single centre in Sweden. Vasa. 2012, 41: 43-48. 10.1024/0301-1526/a000162.CrossRefPubMed Alhadad A, Wollmer P, Svensson A, Eriksson KF: Erythromelalgia: incidence and clinical experience in a single centre in Sweden. Vasa. 2012, 41: 43-48. 10.1024/0301-1526/a000162.CrossRefPubMed
8.
go back to reference Cook-Norris RH, Tollefson MM, Cruz-Inigo AE, Sandroni P, Davis MD, Davis DM: Pediatric erythromelalgia: a retrospective review of 32 cases evaluated at Mayo clinic over a 37-year period. J Am Acad Dermatol. 2011, 26: Cook-Norris RH, Tollefson MM, Cruz-Inigo AE, Sandroni P, Davis MD, Davis DM: Pediatric erythromelalgia: a retrospective review of 32 cases evaluated at Mayo clinic over a 37-year period. J Am Acad Dermatol. 2011, 26:
9.
go back to reference Han C, Rush AM, Dib-Hajj SD, Li S, Xu Z, Wang Y, Tyrrell L, Wang X, Yang Y, Waxman SG: Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7. Annals of Neurology. 2006, 59: 553-558. 10.1002/ana.20776.CrossRefPubMed Han C, Rush AM, Dib-Hajj SD, Li S, Xu Z, Wang Y, Tyrrell L, Wang X, Yang Y, Waxman SG: Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7. Annals of Neurology. 2006, 59: 553-558. 10.1002/ana.20776.CrossRefPubMed
10.
go back to reference Estacion M, Dib-Hajj SD, Benke PJ, te Morsche RH, Eastman EM, Macala LJ, Drenth JP, Waxman SG: Nav1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci. 2008, 28: 11079-11088. 10.1523/JNEUROSCI.3443-08.2008.CrossRefPubMed Estacion M, Dib-Hajj SD, Benke PJ, te Morsche RH, Eastman EM, Macala LJ, Drenth JP, Waxman SG: Nav1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci. 2008, 28: 11079-11088. 10.1523/JNEUROSCI.3443-08.2008.CrossRefPubMed
11.
go back to reference Dib-Hajj SD, Rush AM, Cummins TR, Hisama FM, Novella S, Tyrrell L, Marshall L, Waxman SG: Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain. 2005, 128: 1847-1854. 10.1093/brain/awh514.CrossRefPubMed Dib-Hajj SD, Rush AM, Cummins TR, Hisama FM, Novella S, Tyrrell L, Marshall L, Waxman SG: Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain. 2005, 128: 1847-1854. 10.1093/brain/awh514.CrossRefPubMed
12.
go back to reference Dupont E, Illum F, Olivarius Bde F: Bromocriptine and erythromelalgia-like eruptions. Neurology. 1983, 33: 670-CrossRefPubMed Dupont E, Illum F, Olivarius Bde F: Bromocriptine and erythromelalgia-like eruptions. Neurology. 1983, 33: 670-CrossRefPubMed
13.
go back to reference Kvernebo K: Erythromelalgia – a condition caused by microvascular arteriovenous shunting. Vasa. 1998, 51 (Suppl): 1-39. Kvernebo K: Erythromelalgia – a condition caused by microvascular arteriovenous shunting. Vasa. 1998, 51 (Suppl): 1-39.
14.
go back to reference Mork C, Asker CL, Salerud EG, Kvernebo K: Microvascular arteriovenous shunting is probable pathogenetic mechanism in erythromelalgia. J Invest Dermatol. 2000, 114: 643-646. 10.1046/j.1523-1747.2000.00944.x.CrossRefPubMed Mork C, Asker CL, Salerud EG, Kvernebo K: Microvascular arteriovenous shunting is probable pathogenetic mechanism in erythromelalgia. J Invest Dermatol. 2000, 114: 643-646. 10.1046/j.1523-1747.2000.00944.x.CrossRefPubMed
15.
go back to reference Mork C, Kalgaard OM, Kvernebo K: Impaired neurogenic control of skin perfusion in erythromelalgia. J Invest Dermatol. 2002, 118: 699-703. 10.1046/j.1523-1747.2002.01726.x.CrossRefPubMed Mork C, Kalgaard OM, Kvernebo K: Impaired neurogenic control of skin perfusion in erythromelalgia. J Invest Dermatol. 2002, 118: 699-703. 10.1046/j.1523-1747.2002.01726.x.CrossRefPubMed
16.
go back to reference Orstavik K, Weidner C, Schmidt R, Schmelz M, Hilliges M, Jorum E, Handwerker H, Torebjork E: Pathological C-fibres in patients with a chronic painful condition. Brain. 2003, 126: 567-578. 10.1093/brain/awg060.CrossRefPubMed Orstavik K, Weidner C, Schmidt R, Schmelz M, Hilliges M, Jorum E, Handwerker H, Torebjork E: Pathological C-fibres in patients with a chronic painful condition. Brain. 2003, 126: 567-578. 10.1093/brain/awg060.CrossRefPubMed
17.
go back to reference Davis MD, Sandroni P, Rooke TW, Low PA: Erythromelalgia: vasculopathy, neuropathy or both?. Arch Dermatol. 2003, 139: 1337-1343.CrossRefPubMed Davis MD, Sandroni P, Rooke TW, Low PA: Erythromelalgia: vasculopathy, neuropathy or both?. Arch Dermatol. 2003, 139: 1337-1343.CrossRefPubMed
18.
go back to reference Kim MK, Yuk JW, Kim HS, Park KJ, Kim DS: Autonomic dysfunction in SCN9A-associated primary erythromelalgia. Clin Auton Res. 2013, 23: 105-107. 10.1007/s10286-012-0181-7.CrossRefPubMed Kim MK, Yuk JW, Kim HS, Park KJ, Kim DS: Autonomic dysfunction in SCN9A-associated primary erythromelalgia. Clin Auton Res. 2013, 23: 105-107. 10.1007/s10286-012-0181-7.CrossRefPubMed
19.
go back to reference Cummins TR, Dib-Hajj SD, Waxman SG: Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci. 2004, 24: 8232-8236. 10.1523/JNEUROSCI.2695-04.2004.CrossRefPubMed Cummins TR, Dib-Hajj SD, Waxman SG: Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci. 2004, 24: 8232-8236. 10.1523/JNEUROSCI.2695-04.2004.CrossRefPubMed
20.
go back to reference Cheng X, Dib-Hajj SD, Tyrrell L, Te Morsche RH, Drenth JP, Waxman SG: Deletion mutation of sodium channel Na(V)1.7 in inherited erythromelalgia: enhanced slow inactivation modulates dorsal root ganglion neuron hyperexcitability. Brain. 2011, 134: 1972-1986. 10.1093/brain/awr143.CrossRefPubMed Cheng X, Dib-Hajj SD, Tyrrell L, Te Morsche RH, Drenth JP, Waxman SG: Deletion mutation of sodium channel Na(V)1.7 in inherited erythromelalgia: enhanced slow inactivation modulates dorsal root ganglion neuron hyperexcitability. Brain. 2011, 134: 1972-1986. 10.1093/brain/awr143.CrossRefPubMed
21.
go back to reference Dib-Hajj SD, Cummins TR, Black JA, Waxman SG: From genes to pain: Nav1.7 and human pain disorders. Trends Neurosci. 2007, 30: 555-563. 10.1016/j.tins.2007.08.004.CrossRefPubMed Dib-Hajj SD, Cummins TR, Black JA, Waxman SG: From genes to pain: Nav1.7 and human pain disorders. Trends Neurosci. 2007, 30: 555-563. 10.1016/j.tins.2007.08.004.CrossRefPubMed
22.
go back to reference Drenth JP, Waxman SG: Mutations in sodium channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest. 2007, 117: 3603-3609. 10.1172/JCI33297.CrossRefPubMedPubMedCentral Drenth JP, Waxman SG: Mutations in sodium channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest. 2007, 117: 3603-3609. 10.1172/JCI33297.CrossRefPubMedPubMedCentral
23.
go back to reference Dib-Hajj SD, Yang Y, Black JA, Waxman SG: The Nav1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2012, 14: 49-62.CrossRefPubMed Dib-Hajj SD, Yang Y, Black JA, Waxman SG: The Nav1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2012, 14: 49-62.CrossRefPubMed
24.
go back to reference Min-Tzu W, Po-Yuan H, Chen-Tung Y, Chih-Cheng C, Ming-Jen L: A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers. PLoS One. 2013, 8: e55212-10.1371/journal.pone.0055212.CrossRef Min-Tzu W, Po-Yuan H, Chen-Tung Y, Chih-Cheng C, Ming-Jen L: A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers. PLoS One. 2013, 8: e55212-10.1371/journal.pone.0055212.CrossRef
25.
go back to reference Skeik N, Rooke TW, Davis MD, Davis DM, Kalsi H, Kurth I, Richardson RC: Severe case and literature review of primary erythromelalgia: novel SCN9A gene mutation. Vasc Med. 2012, 17: 44-49. 10.1177/1358863X11422584.CrossRefPubMed Skeik N, Rooke TW, Davis MD, Davis DM, Kalsi H, Kurth I, Richardson RC: Severe case and literature review of primary erythromelalgia: novel SCN9A gene mutation. Vasc Med. 2012, 17: 44-49. 10.1177/1358863X11422584.CrossRefPubMed
27.
go back to reference Ozsoylu S, Caner H, Gökalp A: Successful treatment of erythromelalgia with sodium nitroprusside. J Pediatr. 1979, 94: 619-621.CrossRefPubMed Ozsoylu S, Caner H, Gökalp A: Successful treatment of erythromelalgia with sodium nitroprusside. J Pediatr. 1979, 94: 619-621.CrossRefPubMed
28.
go back to reference Nathan A, Rose JB, Guite JW, Hehir D, Milovcich K: Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. Pediatrics. 2005, 115: e504-e507. 10.1542/peds.2004-1395.CrossRefPubMed Nathan A, Rose JB, Guite JW, Hehir D, Milovcich K: Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. Pediatrics. 2005, 115: e504-e507. 10.1542/peds.2004-1395.CrossRefPubMed
29.
go back to reference Cohen JS: High-dose oral magnesium treatment of chronic, intractable erythromelalgia. Ann Pharmacother. 2002, 36: 255-260.CrossRefPubMed Cohen JS: High-dose oral magnesium treatment of chronic, intractable erythromelalgia. Ann Pharmacother. 2002, 36: 255-260.CrossRefPubMed
30.
go back to reference Davis MD, Sandroni P: Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch Dermatol. 2005, 141: 1320-1321.CrossRefPubMed Davis MD, Sandroni P: Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch Dermatol. 2005, 141: 1320-1321.CrossRefPubMed
31.
go back to reference Iqbal J, Bhat MI, Charoo BA, Syed WA, Sheikh MA, Bhat IN: Experience with oral mexiletine in primary erythromelalgia in children. Ann Saudi Med. 2009, 29: 316-318. 10.4103/0256-4947.55316.CrossRefPubMedPubMedCentral Iqbal J, Bhat MI, Charoo BA, Syed WA, Sheikh MA, Bhat IN: Experience with oral mexiletine in primary erythromelalgia in children. Ann Saudi Med. 2009, 29: 316-318. 10.4103/0256-4947.55316.CrossRefPubMedPubMedCentral
32.
go back to reference Legroux-Crespel E, Sassolas B, Guillet G: Treatment of familial erythermalgia with the association of lidocaine and mexiletine. Ann Dermatol Venereol. 2003, 130: 429-433.PubMed Legroux-Crespel E, Sassolas B, Guillet G: Treatment of familial erythermalgia with the association of lidocaine and mexiletine. Ann Dermatol Venereol. 2003, 130: 429-433.PubMed
33.
go back to reference Goldberg YP, Price N, Namdari R, Cohen CJ, Lamers MH, Winters C, Price J, Young CE, Verschoof H, Sherrington R, Pimstone SN, Hayden MR: Treatment of Nav1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012, 153: 80-85. 10.1016/j.pain.2011.09.008.CrossRefPubMed Goldberg YP, Price N, Namdari R, Cohen CJ, Lamers MH, Winters C, Price J, Young CE, Verschoof H, Sherrington R, Pimstone SN, Hayden MR: Treatment of Nav1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012, 153: 80-85. 10.1016/j.pain.2011.09.008.CrossRefPubMed
34.
go back to reference Davis MD, Rooke T: Erythromelalgia. Current Treatment Options in Cardiovascular Medicine. 2006, 8: 153-165. 10.1007/s11936-006-0008-8.CrossRefPubMed Davis MD, Rooke T: Erythromelalgia. Current Treatment Options in Cardiovascular Medicine. 2006, 8: 153-165. 10.1007/s11936-006-0008-8.CrossRefPubMed
35.
go back to reference Fischer TZ, Gilmore ES, Estacion M, Eastman E, Taylor S, Melanson M, Dib-Hajj SD, Waxman SG: A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. Ann Neurol. 2009, 65: 733-741. 10.1002/ana.21678.CrossRefPubMedPubMedCentral Fischer TZ, Gilmore ES, Estacion M, Eastman E, Taylor S, Melanson M, Dib-Hajj SD, Waxman SG: A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. Ann Neurol. 2009, 65: 733-741. 10.1002/ana.21678.CrossRefPubMedPubMedCentral
36.
go back to reference Yang Y, Dib-Hajj SD, Zhang J, Zhang Y, Tyrrell L, Estacion M, Waxman SG: Structural modeling and mutant cycle analysis predict pharmacoresponsiveness of a Nav1.7 mutant channel. Nature Comm. 2012, 3: 1186-CrossRef Yang Y, Dib-Hajj SD, Zhang J, Zhang Y, Tyrrell L, Estacion M, Waxman SG: Structural modeling and mutant cycle analysis predict pharmacoresponsiveness of a Nav1.7 mutant channel. Nature Comm. 2012, 3: 1186-CrossRef
38.
go back to reference Sakakibara R, Fukutake T, Kita K: Treatment of erythromelalgia with cyproheptadine. J Auton Nerv Syst. 1996, 58: 121-122. 10.1016/0165-1838(95)00121-2.CrossRefPubMed Sakakibara R, Fukutake T, Kita K: Treatment of erythromelalgia with cyproheptadine. J Auton Nerv Syst. 1996, 58: 121-122. 10.1016/0165-1838(95)00121-2.CrossRefPubMed
39.
go back to reference Moody S, Pacheco S, Butler IJ, Koenig MK: Secondary erythromelalgia successfully treated with intravenous immunoglobulin. J Child Neurol. 2012, 27: 922-923. 10.1177/0883073811427784.CrossRefPubMed Moody S, Pacheco S, Butler IJ, Koenig MK: Secondary erythromelalgia successfully treated with intravenous immunoglobulin. J Child Neurol. 2012, 27: 922-923. 10.1177/0883073811427784.CrossRefPubMed
Metadata
Title
An Egyptian child with erythromelalgia responding to a new line of treatment: a case report and review of the literature
Authors
Samir M Al-Minshawy
Abdel-Azeem M El-Mazary
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2014
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-8-69

Other articles of this Issue 1/2014

Journal of Medical Case Reports 1/2014 Go to the issue